Document Detail

Impact of therapy on the outcome of chronic hepatitis B.
MedLine Citation:
PMID:  23286854     Owner:  NLM     Status:  In-Data-Review    
Chronic hepatitis B virus (HBV) infection is a dynamic state in which HBV replication is the key driving force of disease progression, resulting in the development of hepatic decompensation, cirrhosis and hepatocellular carcinoma (HCC). The primary aim of therapy is to eliminate or suppress HBV to reduce the activity of hepatitis thus reducing the risk of or slowing the progression of liver disease. Treatment with nucleos(t)ide analogues (Nuc) may result in rapid suppression of HBV replication with normalization of serum transaminases and restore liver function thus increasing survival in patients with hepatic decompensation. The long-term benefits of a finite course of interferon α (IFN) therapy include a sustained and cumulative response, as well as a reduction in the progression of fibrosis and in the development of cirrhosis and/or HCC. Long-term Nuc therapy may also result in histological improvement or reversal of advanced fibrosis and reduction in disease progression including the development of HCC. Hepatitis B surface antigen (HBsAg) seroclearance, a status close to a "cure", may also occur in patients with a sustained or maintained viral response, especially in those with IFN-based therapy. Pegylated IFN (PEG-IFN) and newer Nucs may have even better long-term outcomes because of improved efficacy and/or a low risk of drug resistance. However, treatment outcomes are still far from satisfactory. The development of more effective and safe but affordable anti-HBV agents/strategies is needed to further improve outcomes.
Yun-Fan Liaw
Related Documents :
23918244 - Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuat...
11231184 - Epidemiology of human immunodeficiency virus and acquired immunodeficiency syndrome in ...
16146764 - Hiv disorders of the brain: pathology and pathogenesis.
8865824 - Hiv infection and aids in jerusalem: a microcosm of illness in israel.
7827214 - Viral antibodies in recent onset, nonorganic psychoses: correspondence with symptomatic...
15123854 - Antiretrovirals, part 1: overview, history, and focus on protease inhibitors.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  111-5     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
Next Document:  Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resista...